Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

The inflammasome-mediated cleavage of gasdermin D (GSDMD) causes pyroptosis and
inflammatory cytokine release to control pathogen infection, but how pathogens evade this …

The remarkable ability of Mycobacterium tuberculosis to survive attacks from the host
immune response and drug treatment is due to the resilience of a few bacilli rather than a …

Model‐informed drug development (MIDD) has a long and rich history in infectious
diseases. This review describes foundational principles of translational anti‐infective …

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a potentially fatal infectious
disease requiring long treatment duration with multiple antibiotics and against which there is …

Preclinical analysis of drug efficacy is critical for drug development. However, conventional
bulk-cell assays statically assess the mean population behavior, lacking resolution on drug …

Imperfect medication adherence remains the biggest predictor of treatment failure for
patients with tuberculosis. Missed doses during treatment lead to relapse, tuberculosis …

The value of model‐based translation in drug discovery and development is now effectively
being recognized in many disease areas and among various stakeholders. Such …

Nitrobenzothiazinones (BTZs) are a very potent class of antibiotics against Mycobacterium
tuberculosis. However, relationships between their structural properties and whole cell …